Low Dose Infliximab for Prevention of Postoperative Recurrence of Crohn's Disease: Long Term Follow-Up and Impact of Infliximab Trough Levels and Antibodies to Infliximab.
<h4>Objective</h4>In patients with postoperative recurrence of Crohn's disease endoscopic and clinical remission can be maintained for up to 1 year with low infliximab doses (3 mg/Kg). However, in theory low-dose infliximab treated patients could develop subtherapeutic trough levels...
Saved in:
| Main Authors: | Dario Sorrentino, Marco Marino, Themistocles Dassopoulos, Dimitra Zarifi, Tiziana Del Bianco |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0144900&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Study Investigating the Association of Dermatological and Infusion Reactions to Infliximab and Infliximab Trough Levels
by: Vivian Wai-Mei Huang, et al.
Published: (2015-01-01) -
Infliximab in the Treatment of Crohn’s Disease
by: Brian Feagan
Published: (2000-01-01) -
Comparison of endoscopic healing and durability between combination therapy with infliximab and azathioprine versus infliximab monotherapy in pediatric Crohn’s disease
by: Yoon Zi Kim, et al.
Published: (2025-07-01) -
Listeria Meningitis Complicating Infliximab Treatment for Crohn’s Disease
by: Geoffrey Williams, et al.
Published: (2005-01-01) -
A literature survey on follow-up definitions on the use of infliximab in Crohn’s disease
by: Andy Wai Kan Yeung
Published: (2025-08-01)